{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T23:05:10Z","timestamp":1648767910613},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10165-011-0489-5","type":"journal-article","created":{"date-parts":[[2011,6,28]],"date-time":"2011-06-28T05:50:47Z","timestamp":1309240247000},"page":"280-283","source":"Crossref","is-referenced-by-count":1,"title":["Mycophenolate mofetil therapy for juvenile dermatomyositis with immune thrombocytopenic purpura"],"prefix":"10.1093","volume":"22","author":[{"given":"Chikara","family":"Ogimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazuna","family":"Honma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Oh-ishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,6,28]]},"reference":[{"key":"489_CR1","first-page":"75","volume":"29","author":"C Arnal","year":"2002","unstructured":"Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol. 2002;29:75\u201383.","journal-title":"J Rheumatol"},{"key":"489_CR2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/art.1780261002","volume":"26","author":"MH Miller","year":"1983","unstructured":"Miller MH, Urowitz MB, Gladman DD. The significance of thrombocytopenia in systemic lupus erythematosus. Arthritis Rheum. 1983;26:1181\u20136.","journal-title":"Arthritis Rheum"},{"key":"489_CR3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/03009740510018642","volume":"35","author":"I Kobayashi","year":"2006","unstructured":"Kobayashi I, Kawamura N, Okano M, Sageshima S, Nakayama T, Ohyu J, et al. Thrombocytopenia in juvenile dermatomyositis. Scand J Rheumatol. 2006;35:79\u201380.","journal-title":"Scand J Rheumatol"},{"key":"489_CR4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/0961203308094999","volume":"18","author":"F Falcini","year":"2009","unstructured":"Falcini F, Capannini S, Martini G, La Torre F, Vitale A, Mangiantini F, et al. Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study. Lupus. 2009;18:139\u201343.","journal-title":"Lupus"},{"key":"489_CR5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1191\/0961203303lu417cr","volume":"12","author":"S Vasoo","year":"2003","unstructured":"Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus. 2003;12:630\u20132.","journal-title":"Lupus"},{"key":"489_CR6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/0961203308099242","volume":"18","author":"C Nannini","year":"2009","unstructured":"Nannini C, Crowson CS, Matteson EL, Moder KG. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study. Lupus. 2009;18:394\u20139.","journal-title":"Lupus"},{"key":"489_CR7","first-page":"1","volume":"29","author":"D Alarcon-Segovia","year":"2002","unstructured":"Alarcon-Segovia D. Splenectomy has a limited role in the management of lupus with thrombocytopenia. J Rheumatol. 2002;29:1\u20132.","journal-title":"J Rheumatol"},{"key":"489_CR8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1600-0609.2005.00437.x","volume":"75","author":"R Kotb","year":"2005","unstructured":"Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005;75:60\u20134.","journal-title":"Eur J Haematol"},{"key":"489_CR9","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1745-7254.2005.00088.x","volume":"26","author":"WG Zhang","year":"2005","unstructured":"Zhang WG, Ji L, Cao XM, Chen YX, He AL, Liu J, et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sin. 2005;26:598\u2013602.","journal-title":"Acta Pharmacol Sin"},{"key":"489_CR10","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/art.24631","volume":"60","author":"TJ Richards","year":"2009","unstructured":"Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009;60:2183\u201392.","journal-title":"Arthritis Rheum"},{"key":"489_CR11","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1164\/ajrccm.164.7.2103110","volume":"164","author":"WW Douglas","year":"2001","unstructured":"Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, et al. Polymyositis\u2013dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164:1182\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"489_CR12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1164\/ajrccm.165.3.2107134","volume":"165","author":"H Ohnishi","year":"2002","unstructured":"Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165:378\u201381.","journal-title":"Am J Respir Crit Care Med"},{"key":"489_CR13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10165-007-0610-y","volume":"17","author":"Y Morinishi","year":"2007","unstructured":"Morinishi Y, Oh-Ishi T, Kabuki T, Joh K. Juvenile dermatomyositis: clinical characteristics and the relatively high risk of interstitial lung disease. Mod Rheumatol. 2007;17:413\u20137.","journal-title":"Mod Rheumatol"},{"key":"489_CR14","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/00007890-199712150-00020","volume":"64","author":"DC Gross","year":"1997","unstructured":"Gross DC, Sasaki TM, Buick MK, Light JA. Acute respiratory failure and pulmonary fibrosis secondary to administration of mycophenolate mofetil. Transplantation. 1997;64:1607\u20139.","journal-title":"Transplantation"},{"key":"489_CR15","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1097\/00007890-199805270-00026","volume":"65","author":"P Morrissey","year":"1998","unstructured":"Morrissey P, Gohh R, Madras P, Monaco AP. Pulmonary fibrosis secondary to administration of mycophenolate mofetil. Transplantation. 1998;65:1414.","journal-title":"Transplantation"},{"key":"489_CR16","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/archinte.168.15.1718","volume":"168","author":"LA Saketkoo","year":"2008","unstructured":"Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med. 2008;168:1718\u20139.","journal-title":"Arch Intern Med"},{"key":"489_CR17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.130.1.30","volume":"130","author":"JJ Swigris","year":"2006","unstructured":"Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130:30\u20136.","journal-title":"Chest"},{"key":"489_CR18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1054\/mehy.2001.1437","volume":"57","author":"EL Altschuler","year":"2001","unstructured":"Altschuler EL. Consideration of mycophenolate mofetil for idiopathic pulmonary fibrosis. Med Hypotheses. 2001;57:701\u20132.","journal-title":"Med Hypotheses"},{"key":"489_CR19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/B978-1-4160-0246-8.50024-3","volume-title":"Textbook of pediatric rheumatology","author":"JT Cassidy","year":"2005","unstructured":"Cassidy JT, Lindsley CB. Juvenile dermatomyositis. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 5th ed. Philadelphia: Elsevier Saunders; 2005. p. 407\u201341.","edition":"5"},{"key":"489_CR20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","volume":"44","author":"V Majithia","year":"2005","unstructured":"Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford). 2005;44:386\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"489_CR21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archderm.142.1.65","volume":"142","author":"JC Edge","year":"2006","unstructured":"Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142:65\u20139.","journal-title":"Arch Dermatol"},{"key":"489_CR22","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","volume":"66","author":"J Rowin","year":"2006","unstructured":"Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006;66:1245\u20137.","journal-title":"Neurology"},{"key":"489_CR23","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/acr.20269","volume":"62","author":"KA Rouster-Stevens","year":"2010","unstructured":"Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62:1446\u201351.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10165-011-0489-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:27:46Z","timestamp":1646843266000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-011-0489-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,28]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1007\/s10165-011-0489-5","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,28]]}}}